Skip to main content
Dryad

Tumor RNAseq and nCounter for ERY974 monotherapy and/or combination with chemotherapy

Sano, Yuji1

Published May 19, 2022 on Dryad. https://doi.org/10.5061/dryad.kwh70rz4q

Data files

Abstract

We examined pharmacodynamic (PD) of ERY974, CD3 and GPC3-targeting T cell bispecific antibody (TRAB), in tumors of huminized/NOG mice administered with ERY974 and/or chemotherapy. First, we examined the RNAsea data of ERY974 monothrapy for tumors of PC10, NCI-H446, MKN45, and MKN74 of humanized/NOG mice. We found that gene expression related with immune cells at baseline is correlated with efficacy of ERY974. Then,we examined the PD of ERY974 combined with chemotherapy (paclitaxel, cisplatin and capecitabine). In NCI-H446, a representative of non-inflamed-tumor, we examined the tumor RNA of huminized/NOG mice administered with ERY974 and/or paclitaxel, or cisplatin. In MKN45, a representative of non-inflamed-tumor, we examined the tumor RNA of huminized/NOG mice administered with ERY974 and/or capecitabine. For capecitabine combination, we firstly examined the suitable timing among day 3,7,and 14 when combination effect was cleary observed, and found that day 14 is the most suitable timing. From all the data, we found that combination of chemotherpay increased ERY974-induced gene expression related with T cell marker and T cell activation. To examine if our findings  are observed in other TRABs in common, we parepred for the EGFR-TRAB, and examined the RNA analysis of MKN45 tumor of huminized/NOG mice administred with EGFR-TRAB and/or paclitaxel. We confirmed that paclitaxel increased EGFR-TRAB-induced gene expression related with T cell marker and T cell activation. We concluded that combination of TRABs with chemotharpy is suitable strategy to erradicate non-inflamed tumors.